TW529951B - Pharmaceutical composition comprising a 2- [[(2-pyridinyl) methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such pharmaceutical composition - Google Patents

Pharmaceutical composition comprising a 2- [[(2-pyridinyl) methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such pharmaceutical composition Download PDF

Info

Publication number: TW529951B
Authority: TW; Taiwan
Prior art keywords: pharmaceutical composition; coating; benzimidazole; item; oral pharmaceutical
Prior art date: 1998-03-20

Application number

TW088103837A

Other languages

English (en)

Chinese (zh)

Inventor

Kristian Lund Henriksen

Helle Kann

Karen Eichstedt Sorensen

Soren Bols Pedersen

Original Assignee

Gea Farmaceutisk Fabrik As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-20

Filing date

1999-03-12

Publication date

2003-05-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW529951(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-03-12 Application filed by Gea Farmaceutisk Fabrik As filed Critical Gea Farmaceutisk Fabrik As

2003-05-01 Application granted granted Critical

2003-05-01 Publication of TW529951B publication Critical patent/TW529951B/zh

Links

238000000034 method Methods 0.000 title claims abstract description 25
238000002360 preparation method Methods 0.000 title claims abstract description 14
230000000694 effects Effects 0.000 title claims abstract description 11
230000000767 anti-ulcer Effects 0.000 title claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 title claims description 8
HBDKFZNDMVLSHM-UHFFFAOYSA-N 2-(pyridin-2-ylmethylsulfinyl)-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1S(=O)CC1=CC=CC=N1 HBDKFZNDMVLSHM-UHFFFAOYSA-N 0.000 title abstract 2
238000000576 coating method Methods 0.000 claims abstract description 79
239000011248 coating agent Substances 0.000 claims abstract description 73
239000010410 layer Substances 0.000 claims abstract description 53
239000000203 mixture Substances 0.000 claims abstract description 51
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 37
239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 19
239000004094 surface-active agent Substances 0.000 claims abstract description 19
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims abstract description 17
239000000155 melt Substances 0.000 claims abstract description 17
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 11
239000000194 fatty acid Substances 0.000 claims abstract description 11
229930195729 fatty acid Natural products 0.000 claims abstract description 11
150000004665 fatty acids Chemical class 0.000 claims abstract description 7
150000002148 esters Chemical class 0.000 claims abstract description 5
239000007884 disintegrant Substances 0.000 claims abstract description 4
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 48
229960000381 omeprazole Drugs 0.000 claims description 47
239000003795 chemical substances by application Substances 0.000 claims description 37
239000000463 material Substances 0.000 claims description 27
238000002844 melting Methods 0.000 claims description 20
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 19
230000008018 melting Effects 0.000 claims description 19
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 18
238000003756 stirring Methods 0.000 claims description 18
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
-1 2-pyridinyl Chemical group 0.000 claims description 13
235000011187 glycerol Nutrition 0.000 claims description 12
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 12
239000004480 active ingredient Substances 0.000 claims description 11
239000002270 dispersing agent Substances 0.000 claims description 11
239000000454 talc Substances 0.000 claims description 10
229910052623 talc Inorganic materials 0.000 claims description 10
239000004615 ingredient Substances 0.000 claims description 9
239000004408 titanium dioxide Substances 0.000 claims description 9
229920002472 Starch Polymers 0.000 claims description 8
235000019698 starch Nutrition 0.000 claims description 8
239000008107 starch Substances 0.000 claims description 8
239000000758 substrate Substances 0.000 claims description 8
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 6
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
230000015556 catabolic process Effects 0.000 claims description 6
238000006731 degradation reaction Methods 0.000 claims description 6
239000002245 particle Substances 0.000 claims description 6
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
229930006000 Sucrose Natural products 0.000 claims description 5
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 5
239000011247 coating layer Substances 0.000 claims description 5
238000001816 cooling Methods 0.000 claims description 5
229940075507 glyceryl monostearate Drugs 0.000 claims description 5
239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 5
239000005720 sucrose Substances 0.000 claims description 5
239000001069 triethyl citrate Substances 0.000 claims description 5
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 5
235000013769 triethyl citrate Nutrition 0.000 claims description 5
238000005516 engineering process Methods 0.000 claims description 4
229920003145 methacrylic acid copolymer Polymers 0.000 claims description 4
239000004014 plasticizer Substances 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 3
239000007903 gelatin capsule Substances 0.000 claims description 3
238000010438 heat treatment Methods 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 3
IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 2
125000000129 anionic group Chemical group 0.000 claims description 2
238000000354 decomposition reaction Methods 0.000 claims description 2
239000007888 film coating Substances 0.000 claims description 2
238000009501 film coating Methods 0.000 claims description 2
229960005019 pantoprazole Drugs 0.000 claims description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
239000012752 auxiliary agent Substances 0.000 claims 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
239000003945 anionic surfactant Substances 0.000 claims 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims 1
229960000913 crospovidone Drugs 0.000 claims 1
229910003460 diamond Inorganic materials 0.000 claims 1
239000010432 diamond Substances 0.000 claims 1
230000004907 flux Effects 0.000 claims 1
239000002736 nonionic surfactant Substances 0.000 claims 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
238000009472 formulation Methods 0.000 abstract description 23
239000011159 matrix material Substances 0.000 abstract description 9
239000008187 granular material Substances 0.000 abstract description 8
239000000126 substance Substances 0.000 abstract description 8
238000009505 enteric coating Methods 0.000 abstract description 3
239000002702 enteric coating Substances 0.000 abstract description 3
239000011162 core material Substances 0.000 description 46
239000010408 film Substances 0.000 description 37
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical class C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 21
238000011049 filling Methods 0.000 description 19
150000001875 compounds Chemical class 0.000 description 13
230000002079 cooperative effect Effects 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
235000012222 talc Nutrition 0.000 description 8
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
239000011230 binding agent Substances 0.000 description 7
239000001863 hydroxypropyl cellulose Substances 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
229930195725 Mannitol Natural products 0.000 description 5
150000007514 bases Chemical class 0.000 description 5
239000002775 capsule Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000004090 dissolution Methods 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000003925 fat Substances 0.000 description 5
239000000594 mannitol Substances 0.000 description 5
235000010355 mannitol Nutrition 0.000 description 5
239000000243 solution Substances 0.000 description 5
240000000724 Berberis vulgaris Species 0.000 description 4
235000016068 Berberis vulgaris Nutrition 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000013543 active substance Substances 0.000 description 4
150000001447 alkali salts Chemical class 0.000 description 4
229920001577 copolymer Polymers 0.000 description 4
210000004211 gastric acid Anatomy 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
229960004793 sucrose Drugs 0.000 description 4
238000012360 testing method Methods 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
239000003086 colorant Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 3
229940043264 dodecyl sulfate Drugs 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
229910052720 vanadium Inorganic materials 0.000 description 3
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
229910052693 Europium Inorganic materials 0.000 description 2
240000000731 Fagus sylvatica Species 0.000 description 2
235000010099 Fagus sylvatica Nutrition 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
239000004368 Modified starch Substances 0.000 description 2
244000170916 Paeonia officinalis Species 0.000 description 2
235000006484 Paeonia officinalis Nutrition 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000012670 alkaline solution Substances 0.000 description 2
239000003699 antiulcer agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
229940093265 berberine Drugs 0.000 description 2
QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 2
239000012055 enteric layer Substances 0.000 description 2
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
229940075529 glyceryl stearate Drugs 0.000 description 2
159000000011 group IA salts Chemical class 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
150000002484 inorganic compounds Chemical class 0.000 description 2
229910010272 inorganic material Inorganic materials 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
229960001855 mannitol Drugs 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
235000019426 modified starch Nutrition 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
MTZWHHIREPJPTG-UHFFFAOYSA-N phorone Chemical compound CC(C)=CC(=O)C=C(C)C MTZWHHIREPJPTG-UHFFFAOYSA-N 0.000 description 2
229930193351 phorone Natural products 0.000 description 2
229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
239000000376 reactant Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000005507 spraying Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229940098465 tincture Drugs 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
DSPHFASHOJAOKN-UHFFFAOYSA-N 1-[(7-oxobenzo[a]phenalen-2-yl)amino]anthracene-9,10-dione Chemical compound C1=CC2=CC(NC3=C4C(=O)C5=CC=CC=C5C(C4=CC=C3)=O)=CC(C=3C(=CC=CC=3)C3=O)=C2C3=C1 DSPHFASHOJAOKN-UHFFFAOYSA-N 0.000 description 1
MJRYPELKKIPFMR-UHFFFAOYSA-N 3,3-dihydroxypropyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCC(O)O MJRYPELKKIPFMR-UHFFFAOYSA-N 0.000 description 1
AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 1
241000208140 Acer Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
240000005979 Hordeum vulgare Species 0.000 description 1
235000007340 Hordeum vulgare Nutrition 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
244000179970 Monarda didyma Species 0.000 description 1
235000010672 Monarda didyma Nutrition 0.000 description 1
HDVDLQFPDLTOSI-UHFFFAOYSA-L O[AlH]O Chemical class O[AlH]O HDVDLQFPDLTOSI-UHFFFAOYSA-L 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
241000287462 Phalacrocorax carbo Species 0.000 description 1
229920003110 Primojel Polymers 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
241000220317 Rosa Species 0.000 description 1
240000000111 Saccharum officinarum Species 0.000 description 1
235000007201 Saccharum officinarum Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
239000003513 alkali Substances 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
230000003254 anti-foaming effect Effects 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229920003020 cross-linked polyethylene Polymers 0.000 description 1
239000004703 cross-linked polyethylene Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229940031954 dibutyl sebacate Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
229960001596 famotidine Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
JDSGZXQTMXKHCQ-UHFFFAOYSA-N formaldehyde;2-methylprop-2-enoic acid Chemical compound O=C.CC(=C)C(O)=O JDSGZXQTMXKHCQ-UHFFFAOYSA-N 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
235000019580 granularity Nutrition 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
150000002597 lactoses Chemical class 0.000 description 1
229960003174 lansoprazole Drugs 0.000 description 1
MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
150000002696 manganese Chemical class 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000012768 molten material Substances 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229910052762 osmium Inorganic materials 0.000 description 1
SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
208000000689 peptic esophagitis Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000005498 phthalate group Chemical class 0.000 description 1
SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
229940126409 proton pump inhibitor Drugs 0.000 description 1
239000000612 proton pump inhibitor Substances 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000008279 sol Substances 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
229940071117 starch glycolate Drugs 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000012257 stirred material Substances 0.000 description 1
238000009498 subcoating Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229960004016 sucrose syrup Drugs 0.000 description 1
125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
150000003455 sulfinic acids Chemical class 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229910052716 thallium Inorganic materials 0.000 description 1
BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
239000010409 thin film Substances 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
125000005591 trimellitate group Chemical group 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

TW088103837A 1998-03-20 1999-03-12 Pharmaceutical composition comprising a 2- [[(2-pyridinyl) methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such pharmaceutical composition TW529951B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK199800397A DK173431B1 (da)	1998-03-20	1998-03-20	Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs

Publications (1)

Publication Number	Publication Date
TW529951B true TW529951B (en)	2003-05-01

Family

ID=8093069

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW088103837A TW529951B (en)	1998-03-20	1999-03-12	Pharmaceutical composition comprising a 2- [[(2-pyridinyl) methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such pharmaceutical composition

Country Status (20)

Country	Link
US (1)	US6391342B1 (is)
EP (1)	EP1061920B1 (is)
AR (1)	AR014753A1 (is)
AT (1)	ATE218863T1 (is)
AU (1)	AU744596B2 (is)
CA (1)	CA2323536C (is)
CZ (1)	CZ291943B6 (is)
DE (1)	DE69901804T2 (is)
DK (2)	DK173431B1 (is)
EA (1)	EA002502B1 (is)
ES (1)	ES2177246T3 (is)
HU (1)	HU226580B1 (is)
IS (1)	IS2265B (is)
NO (1)	NO20004667L (is)
NZ (1)	NZ507115A (is)
PL (1)	PL192437B1 (is)
TR (1)	TR200002696T2 (is)
TW (1)	TW529951B (is)
WO (1)	WO1999048498A1 (is)
ZA (1)	ZA200004757B (is)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2298823C (en) *	1998-04-20	2011-06-07	Eisai Co., Ltd.	Stabilized composition comprising a benzimidazole type compound
ZA9810765B (en) *	1998-05-28	1999-08-06	Ranbaxy Lab Ltd	Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2376202C (en)	1999-06-07	2008-11-18	Byk Gulden Lomberg Chemische Fabrik Gmbh	Novel preparation and administration form comprising an acid-labile active compound
EP1064938A1 (en) *	1999-06-28	2001-01-03	Sanofi-Synthelabo	Pharmaceutical dosage forms for controlled release producing at least a timed pulse
ES2168043B1 (es)	1999-09-13	2003-04-01	Esteve Labor Dr	Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AR021347A1 (es)	1999-10-20	2002-07-17	Cipla Ltd	Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
AU2127200A (en) *	1999-11-02	2001-05-14	Cipla Limited	A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereofand a process of preparing thereof
US20030180352A1 (en) *	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) *	1999-11-23	2006-02-16	Mahesh Patel	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19959419A1 (de)	1999-12-09	2001-06-21	Ratiopharm Gmbh	Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ES2191521B1 (es) *	2000-11-22	2005-02-16	Laboratorios Belmac, S.A.	Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
MY148805A (en) *	2002-10-16	2013-05-31	Takeda Pharmaceutical	Controlled release preparation
WO2004089333A2 (en) *	2003-02-28	2004-10-21	Cadila Healthcare Limited	A stable benzimidazole formulation
ES2234393B2 (es) *	2003-04-29	2006-09-01	Laboratorios Belmac, S.A.	"formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
TWI372066B (en) *	2003-10-01	2012-09-11	Wyeth Corp	Pantoprazole multiparticulate formulations
KR101148734B1 (ko) *	2003-10-10	2012-07-05	에띠빠흠	징코 빌로바 추출물을 포함하는 서방형 미세과립 및 이것을 제조하는 방법
EP1699458A4 (en) *	2003-12-30	2012-04-25	Reddys Lab Ltd Dr	PHARMACEUTICAL COMPOSITION
US20050181052A1 (en) *	2004-02-17	2005-08-18	Patel Satishkumar A.	Lansoprazole microtablets
US20050214372A1 (en) *	2004-03-03	2005-09-29	Simona Di Capua	Stable pharmaceutical composition comprising an acid labile drug
PT1746980E (pt)	2004-05-07	2012-01-25	Nycomed Gmbh	Forma de dosagem farmacêutica compreendendo granulados assim como o seu processo de fabrico
US8461187B2 (en) *	2004-06-16	2013-06-11	Takeda Pharmaceuticals U.S.A., Inc.	Multiple PPI dosage form
JP2009519943A (ja) *	2005-12-16	2009-05-21	タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド	イラプラゾールの医薬組成物
WO2007100984A2 (en) *	2006-02-24	2007-09-07	Allergan, Inc.	Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
AU2007266574A1 (en) *	2006-06-01	2007-12-06	Dexcel Pharma Technologies Ltd.	Multiple unit pharmaceutical formulation
US8486452B2 (en)	2007-07-20	2013-07-16	Mylan Pharmaceuticals Inc.	Stabilized tolterodine tartrate formulations
US8110226B2 (en) *	2007-07-20	2012-02-07	Mylan Pharmaceuticals Inc.	Drug formulations having inert sealed cores
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US20100239681A1 (en) *	2009-03-20	2010-09-23	Biokey, Inc.	Controlled Release Particulates Containing Water-Insoluble Drug
WO2010122583A2 (en)	2009-04-24	2010-10-28	Rubicon Research Private Limited	Oral pharmaceutical compositions of acid labile substances
EP2319504A1 (en) *	2009-11-07	2011-05-11	Laboratorios Del. Dr. Esteve, S.A.	Pharmaceutical solid dosage form
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
CN103202820B (zh) *	2012-01-11	2016-03-30	浙江亚太药业股份有限公司	一种稳定的兰索拉唑肠溶胶囊及其制备方法
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016174664A1 (en)	2015-04-29	2016-11-03	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
WO2017145146A1 (en)	2016-02-25	2017-08-31	Dexcel Pharma Technologies Ltd.	Compositions comprising proton pump inhibitors
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
TWI795381B (zh)	2016-12-21	2023-03-11	比利時商健生藥品公司	作為ｍａｌｔ１抑制劑之吡唑衍生物
AU2019308326B2 (en)	2018-07-20	2025-07-31	Lipocine Inc.	Liver disease
ES2949871T3 (es)	2019-04-11	2023-10-03	Janssen Pharmaceutica Nv	Anillos de piridina que contienen derivados como inhibidores de MALT1

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8301182D0 (sv)	1983-03-04	1983-03-04	Haessle Ab	Novel compounds
CA1327010C (en)	1986-02-13	1994-02-15	Tadashi Makino	Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en)	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
GB2189699A (en)	1986-04-30	1987-11-04	Haessle Ab	Coated acid-labile medicaments
US5026560A (en)	1987-01-29	1991-06-25	Takeda Chemical Industries, Ltd.	Spherical granules having core and their production
ES2024993A6 (es)	1990-12-31	1992-03-01	Genesis Para La Investigacion	Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
TW209174B (is)	1991-04-19	1993-07-11	Takeda Pharm Industry Co Ltd
YU48263B (sh)	1991-06-17	1997-09-30	Byk Gulden Lomberg Chemische Fabrik Gmbh.	Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DE69127275T2 (de) *	1991-06-21	1998-03-12	Ilsan Ilac Ve Hammaddeleri San	Neues galenisches Verfahren für Omeprazol enthaltende Pellets
SE9200858L (sv)	1992-03-20	1993-09-21	Kabi Pharmacia Ab	Metod för framställning av pellets med fördröjd frisättning
FR2692146B1 (fr)	1992-06-16	1995-06-02	Ethypharm Sa	Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en)	1992-07-17	1994-02-03	Astra Aktiebolag	Pharmaceutical composition containing antiulcer agent
ES2087823B1 (es)	1994-07-13	1997-02-16	Estudes Et Richerches Pharma E	Formulacion de microgranulos gastroresistentes de omeprazol y su procedimiento de fabricacion.
ES2094694B1 (es)	1995-02-01	1997-12-16	Esteve Quimica Sa	Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv)	1995-02-09	1995-02-09	Astra Ab	New pharmaceutical formulation and process
US5708017A (en) *	1995-04-04	1998-01-13	Merck & Co., Inc.	Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
CH687810A5 (de)	1995-05-24	1997-02-28	Mepha Ag	Pelletformulierung mit Omeprazol.
US6207198B1 (en)	1995-09-21	2001-03-27	Schwarz Pharma Ag	Composition containing an acid-labile omeprazole and process for its preparation
SE9600072D0 (sv) *	1996-01-08	1996-01-08	Astra Ab	New oral formulation of two active ingredients II
PT101826A (pt)	1996-02-06	1997-09-30	Medinfar Produtos Farmaceutico	Processo para a preparacao de microgranulos contendo omeprazole
EP0968204A1 (en)	1997-03-07	2000-01-05	A/S GEA Farmaceutisk Fabrik	Process for the preparation of 2- (2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose

1998
- 1998-03-20 DK DK199800397A patent/DK173431B1/da not_active IP Right Cessation
1999
- 1999-03-12 TW TW088103837A patent/TW529951B/zh active
- 1999-03-17 EA EA200000970A patent/EA002502B1/ru not_active IP Right Cessation
- 1999-03-17 WO PCT/DK1999/000137 patent/WO1999048498A1/en not_active Ceased
- 1999-03-17 PL PL342840A patent/PL192437B1/pl not_active IP Right Cessation
- 1999-03-17 AU AU27148/99A patent/AU744596B2/en not_active Ceased
- 1999-03-17 AT AT99907346T patent/ATE218863T1/de not_active IP Right Cessation
- 1999-03-17 US US09/646,486 patent/US6391342B1/en not_active Expired - Fee Related
- 1999-03-17 ES ES99907346T patent/ES2177246T3/es not_active Expired - Lifetime
- 1999-03-17 CA CA002323536A patent/CA2323536C/en not_active Expired - Fee Related
- 1999-03-17 EP EP99907346A patent/EP1061920B1/en not_active Expired - Lifetime
- 1999-03-17 DK DK99907346T patent/DK1061920T3/da active
- 1999-03-17 DE DE69901804T patent/DE69901804T2/de not_active Expired - Fee Related
- 1999-03-17 TR TR2000/02696T patent/TR200002696T2/xx unknown
- 1999-03-17 NZ NZ507115A patent/NZ507115A/xx unknown
- 1999-03-17 HU HU0101178A patent/HU226580B1/hu not_active IP Right Cessation
- 1999-03-17 CZ CZ20003458A patent/CZ291943B6/cs not_active IP Right Cessation
- 1999-03-19 AR ARP990101230A patent/AR014753A1/es not_active Application Discontinuation
2000
- 2000-09-08 ZA ZA200004757A patent/ZA200004757B/xx unknown
- 2000-09-13 IS IS5628A patent/IS2265B/is unknown
- 2000-09-19 NO NO20004667A patent/NO20004667L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ATE218863T1 (de)	2002-06-15
HUP0101178A2 (hu)	2001-08-28
PL342840A1 (en)	2001-07-16
DK39798A (da)	1999-09-21
HU226580B1 (en)	2009-04-28
ES2177246T3 (es)	2002-12-01
EP1061920A1 (en)	2000-12-27
US6391342B1 (en)	2002-05-21
TR200002696T2 (tr)	2000-12-21
IS5628A (is)	2000-09-13
NO20004667D0 (no)	2000-09-19
CA2323536C (en)	2009-05-19
EP1061920B1 (en)	2002-06-12
DK173431B1 (da)	2000-10-23
NO20004667L (no)	2000-11-09
WO1999048498A1 (en)	1999-09-30
DE69901804D1 (de)	2002-07-18
AU2714899A (en)	1999-10-18
DE69901804T2 (de)	2002-12-12
IS2265B (is)	2007-07-15
AU744596B2 (en)	2002-02-28
CZ291943B6 (cs)	2003-06-18
NZ507115A (en)	2002-09-27
EA002502B1 (ru)	2002-06-27
CZ20003458A3 (cs)	2001-03-14
DK1061920T3 (da)	2002-07-15
AR014753A1 (es)	2001-03-28
CA2323536A1 (en)	1999-09-30
ZA200004757B (en)	2001-05-30
PL192437B1 (pl)	2006-10-31
EA200000970A1 (ru)	2001-02-26

Publication	Publication Date	Title
TW529951B (en)	2003-05-01	Pharmaceutical composition comprising a 2- [[(2-pyridinyl) methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such pharmaceutical composition
EP0502556B1 (en)	1996-06-26	Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of acid labile compounds
US20040213847A1 (en)	2004-10-28	Delayed release pharmaceutical compositions containing proton pump inhibitors
TWI354569B (en)	2011-12-21	Coated tablet formulation and method
JP4293750B2 (ja)	2009-07-08	ベンズイミダゾール誘導体を含む経口投与製剤及びその製造方法
CN103442727B (zh)	2016-08-10	多微粒l-薄荷醇制剂及相关方法
RS52088B (sr)	2012-06-30	Oblik za oralnu primenu etilestra 3-[(2-{[4-(heksiloksikarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benzimidazol-5-karbonil)-piridin-2-il-amino]propionske kiseline i njegovih soli
TW200824723A (en)	2008-06-16	Pharmaceutical composition
JPWO2017018473A1 (ja)	2018-05-17	錠剤
EP1187599A1 (en)	2002-03-20	Stable benzimidazole formulation
CN107260700A (zh)	2017-10-20	一种替格瑞洛复方口服固体制剂的制备方法
US9114085B2 (en)	2015-08-25	Modified release pharmaceutical compositions of dexlansoprazole
US20140030328A1 (en)	2014-01-30	Dual release oral tablet compositions of dexlansoprazole
US20140023709A1 (en)	2014-01-23	Oral tablet compositions of dexlansoprazole
JP2012514648A (ja)	2012-06-28	経口腸溶性抗うつ薬製剤
JP2813809B2 (ja)	1998-10-22	有核顆粒製剤およびその製造法
CN107019680B (zh)	2019-03-05	一种雷贝拉唑钠肠溶胶囊的制备工艺
CN113318087A (zh)	2021-08-31	埃索美拉唑镁肠溶微丸的制备方法
TW201206502A (en)	2012-02-16	Controlled release nucleated tablet
US20030228363A1 (en)	2003-12-11	Stabilized pharmaceutical compositons containing benzimidazole compounds
WO2003103638A1 (en)	2003-12-18	Stabilized pharmaceutical compositions containing benzimidazole compounds
CN108261409A (zh)	2018-07-10	一种达比加群酯的口服药物组合物及其制备方法
CA2547398A1 (en)	2005-06-09	Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
CN105534939A (zh)	2016-05-04	一种甲磺酸达比加群酯口服固体制剂及其制备方法